Skip to main
ATAI

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

AtaiBeckley is well-positioned for success in the mental health treatment space, with its promising pipeline of novel therapies and strategic acquisitions such as the recent deal with Eli Lilly. BPL-003, the company's lead asset, has a strong potential to address the unmet needs of treatment-resistant depression with its short treatment duration and potential retreatment flexibility. Additionally, the company's management is focused on practical differentiation and commercial practicality, further emphasizing their potential for success in the market.

Bears say

AtaiBeckley is facing potential setbacks in its clinical pipeline, with the 8mg dose of BPL-003 demonstrating low efficacy and VLS-01 requiring strong results in Phase 3 to justify further investment. Furthermore, management's decision to reduce the number of participants in the Phase 2 trial of VLS-01 signals potential concerns about its effectiveness, and the overall package for BPL-003 may not be enough to satisfy regulatory standards.

ATAI has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Buy based on their latest research and market trends.

According to 8 analysts, ATAI has a Buy consensus rating as of Jul 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.